A 510(k) Hold Is Not Yet a Testing Project
Separate an FDA 510(k) RTA or eSTAR completeness hold from substantive testing work by mapping the notice, missing item, owner, response and receipt.
Signals to watch
- A message says RTA hold but does not identify whether FDA issued an acceptance-review result or an eSTAR technical deficiency notice
- The cited deficiency is paraphrased as missing testing although the official notice and checklist item are absent
- The 180-day response limit is running while document, testing, regulatory and applicant owners are not assigned
Treat a 510(k) hold as a notice-and-evidence problem before treating it as a testing project. The first scope must reproduce the FDA communication, identify the submission route and exact missing item, assign an applicant-approved owner, state whether existing evidence can answer it and preserve the replacement or amendment receipt. “RTA—need more testing” is not enough to quote.
Definition: a Refuse to Accept (RTA) decision belongs to FDA’s acceptance-review stage. It says the submission did not meet the minimum threshold to enter substantive review. It is different from an Additional Information request during substantive review, and FDA’s current process treats an incomplete electronic Submission Template And Resource (eSTAR) through technical screening rather than anticipating a conventional RTA review.
Read the subject line before diagnosing the project
A medical-device regulatory consultancy business-development lead may follow authorised Telegram groups used by manufacturers, regulatory professionals, laboratories and product-development teams. A fragment such as the following can arrive before a formal request for proposal:
“510k got RTA. Need someone to fix it fast.”
“Looks like testing section. Team says file was in eSTAR.”
This is an illustrative composite, not a customer message, FDA record or commercial result. It omits the K number, device, submission type, actual FDA subject line, deficiency text, applicant authority, existing test, response date and budget. The second sentence may even combine two different process labels.
The cost of seeing the fragment late is concrete: the applicant may spend days commissioning work that the notice did not request while the actual completeness item remains unanswered. The useful first action is to ask for the official notice and its date, not to promise a laboratory slot.
Three holds can sound identical in a forwarded message
FDA’s current 510(k) Submission Process distinguishes process stages that groups often compress into “RTA.”
| Forwarded label | Official process object | What it establishes | First document to request |
|---|---|---|---|
| Fee or format hold | Hold Letter after missing fee or invalid eSTAR/eCopy | FDA has not completed the basic receipt conditions | Hold Letter, fee record and valid submission-copy evidence |
| RTA hold | Acceptance-review result for the applicable acceptance-checklist route | FDA found the minimum acceptability threshold was not met | RTA notification and cited checklist items |
| eSTAR technical hold | Technical-screening deficiency notice for an incomplete eSTAR | the electronic template is incomplete or technically deficient | deficiency email and the exact eSTAR version submitted |
| AI hold | Additional Information request during substantive review | FDA has begun substantive review and requests additional information | AI request and current review record |
The distinction changes the commercial scope. A fee receipt cannot repair an incomplete test description. A complete replacement eSTAR may resolve a technical deficiency without new testing. An Additional Information request may raise scientific questions that were never part of the RTA checklist. Start from the official object.
The official clock is 15 days for the acceptance result and 180 days for the response limit
For the acceptance-review route, FDA says the submitter receives an electronic result within 15 days of receipt. The result states whether the 510(k) was accepted, refused to accept, or moved into substantive review because FDA did not complete the acceptance review within 15 calendar days.
FDA’s current process page says a submission placed on RTA hold has 180 calendar days to fully address the cited deficiencies. If the response is not complete within that period, FDA considers the submission withdrawn and deletes it from the review system; the submitter would need a new, complete 510(k) to continue pursuing clearance.
For eSTAR, the page says a properly prepared electronic template is not anticipated to undergo the RTA process. If technical screening finds it incomplete, FDA identifies the missing information and holds the submission until a complete replacement eSTAR arrives. The page also states a 180-day limit from that deficiency notice. These are process facts, not advice about whether a specific applicant should submit on a particular date.
Build one deficiency-to-owner-to-receipt row for each cited item
Do not summarize several FDA items as “testing gap.” Preserve one row per cited deficiency:
- Official citation: notice date, section, checklist item and FDA wording.
- Submission location: the eSTAR field, attachment, table or section FDA reviewed.
- Missing object: document, explanation, signed statement, comparison, test evidence, cross-reference or technical correction.
- Current evidence: what exists, its date, configuration and limitation.
- Owner and authority: who can prepare the response and who the applicant authorises to submit or approve it.
- Response action: replace, correct, explain, cross-reference, regenerate or commission new work.
- Receipt: final filename/version, submission date, portal acknowledgement and reopened-status evidence.
This receipt is the article’s original contribution. It prevents a consultancy from selling the most expensive interpretation first. It also makes the response reviewable after team members, laboratories or external writers have changed.
Testing is only one possible missing object
The RTA guidance page describes the policy as a minimum-threshold assessment for substantive review. A cited item may concern administrative completeness, an absent comparison, a missing label, incomplete software documentation, an inadequate description of an existing test or genuinely absent performance evidence. The notice and device-specific context decide which.
Suppose an RTA item points to a missing performance-test report. The applicant might already have a report, but it may identify a different device configuration or omit the protocol and acceptance criteria. The repair may be a configuration bridge and complete report, not new testing. Conversely, a one-page summary cannot replace a study that was never performed. Only the official deficiency, current evidence and qualified technical review can distinguish them.
For a connected-device cybersecurity package, use the FDA Section 524B evidence chain. For establishment-level quality-system scope, the QMSR and ISO 13485 gap-assessment article addresses a different decision. Neither should be imported automatically into an RTA repair.
Early discovery can preserve the notice, but the applicant controls the response
TOP Prospect can retain fragments from Telegram groups the user deliberately connects and is authorised to access, including source, time and original wording for human review. The current production matching-target interface saves configuration but does not automatically create new candidates.
It cannot open an FDA submission, obtain a notice, interpret a device requirement, determine the official correspondent, submit a response or contact the message author. The consultancy lead must obtain applicant permission, verify the notice and route each item to qualified owners. The public product workflow explains that boundary.
Completion test for a bounded remediation scope
A scope is ready for quotation when another authorised reviewer can reproduce all of the following:
- the exact FDA process object and notice date;
- the named device, K number and submission version;
- every cited item and its current submission location;
- the evidence already available and what it cannot answer;
- the response owner, applicant approver and 180-day outside limit;
- the proposed repair output and receipt.
If any of those fields is missing, quote discovery or document review rather than a test programme. The goal is not to make the hold sound small. It is to stop an incomplete group fragment from defining the wrong project.
Key facts
- FDA uses acceptance review to decide whether an applicable 510(k) meets the minimum threshold for substantive review.
- The current process page describes notification of the acceptance result within 15 days of receipt.
- An RTA hold carries a 180-calendar-day limit to fully address cited deficiencies.
- Properly prepared eSTAR submissions are not anticipated to undergo a conventional RTA process; incomplete eSTARs enter technical hold.
- Since 1 October 2023, all 510(k) submissions must use eSTAR unless an FDA exemption applies.
- An RTA decision does not by itself prove that new testing is required.
FAQ
What does an FDA RTA decision mean?
For the acceptance-review route, it means FDA determined that the submission did not meet the minimum threshold for substantive review. It does not by itself state that the device failed a safety or effectiveness test.
How long does a submitter have to address an RTA hold?
FDA’s current 510(k) submission-process page states that a submitter has 180 calendar days to fully address cited RTA deficiencies; otherwise the submission is considered withdrawn and deleted from the review system.
Does every incomplete eSTAR receive an RTA decision?
No. FDA says properly prepared eSTAR submissions are not anticipated to undergo the RTA process. An incomplete eSTAR is placed on hold after technical-screening notification until a complete replacement is submitted.
When should a consultancy quote new testing?
Only when the official notice, cited checklist item and existing submission evidence show that new or revised testing is actually needed. A missing attachment, explanation, form field or cross-reference can require a different repair.
Reviewed by TOP Prospect Editorial Team on 19 August 2026 against the current FDA RTA guidance, 510(k) process and Traditional 510(k) preparation pages. Device classification, submission strategy, deficiency interpretation and response content require qualified review of the actual FDA communication and submission.
Frequently asked questions
What does an FDA RTA decision mean?
For the acceptance-review route, it means FDA determined that the submission did not meet the minimum threshold for substantive review. It does not by itself state that the device failed a safety or effectiveness test.
How long does a submitter have to address an RTA hold?
FDA’s current 510(k) submission-process page states that a submitter has 180 calendar days to fully address cited RTA deficiencies; otherwise the submission is considered withdrawn and deleted from the review system.
Does every incomplete eSTAR receive an RTA decision?
No. FDA says properly prepared eSTAR submissions are not anticipated to undergo the RTA process. An incomplete eSTAR is placed on hold after technical-screening notification until a complete replacement is submitted.
When should a consultancy quote new testing?
Only when the official notice, cited checklist item and existing submission evidence show that new or revised testing is actually needed. A missing attachment, explanation, form field or cross-reference can require a different repair.
Sources and further reading
How a Signal worth attention is found
See how Top Prospect finds and organizes Signals worth checking, keeps the original Telegram context, removes duplicates, and helps you decide what to review first. You decide whether to follow up and what to do next.
